BiVACOR

BiVACOR is a clinical-stage medical device company focused on developing a total artificial heart (TAH) for patients with biventricular heart failure. Founded in 2008 by Dr. Daniel Timms in Australia, the company has its headquarters in Huntington Beach, California, and clinical offices in Houston, Texas, along with international offices in Gold Coast, Australia. The BiVACOR TAH utilizes magnetic levitation (MAGLEV) technology, which allows a dual-sided rotor to operate without valves or flexible chambers, minimizing mechanical wear and blood trauma. This innovative design is capable of providing adequate cardiac output for adult patients, even during physical activity. The device is currently undergoing an FDA-approved Early Feasibility Study, with successful implantation in a patient at Baylor St. Luke’s Medical Center, where it served as a bridge-to-transplant. BiVACOR aims to meet the global demand for durable heart replacement therapies for patients awaiting transplants, collaborating with leading cardiovascular centers to advance its technology.

• Employees 57
• Founded 2008
• Annual Revenue $13500000
• Total Funding $777000003